Critical Reviews in Oncology / Hematology
Volume 73, Issue 1 , Pages 23-30 , January 2010

Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer

  • Sandro Pignata

      Affiliations

    • Medical Oncology, National Cancer Institute, Naples, Italy
    • Corresponding Author InformationCorresponding author at: Instituto Nazionale Tumori de Napoli, Dipartimento Uro-Ginecologico, UOC Oncologia Medica, via M Semmola, Naples, 80131, Italy. Tel.: +39 081 5903637; fax: +39 081 5903861.
    • ,
  • Eric Pujade Lauraine

      Affiliations

    • Medical Oncology, Paris Descartes, AP-HP, Hôtel-Dieu, Paris, France
    • ,
  • Andreas du Bois

      Affiliations

    • Gynecology and Gynecologic Oncology, HSK, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
    • ,
  • Carmela Pisano

      Affiliations

    • Medical Oncology, National Cancer Institute, Naples, Italy

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329
  3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  4. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006;6:5
  5. The ICON and AGO Collaborators . Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106
  6. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707
  7. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393
  8. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–211
  9. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120–3125
  10. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer. 2005;15(Suppl. 1):3–11
  11. Ozols RF, Willson JK, Weltz MD, et al. Inhibition of human ovarian cancer colony formation by Adriamycin and its major metabolites. Cancer Res. 1980;40:4109–4112
  12. A’Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 1995;13:726–732
  13. du Bois A, Weber G, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin–paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol. 2006;24:1127–1135
  14. Kristensen GB, Vergote I, Eisenhauer E, et al. First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(Suppl.) [abstract 5003].
  15. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743
  16. O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–449
  17. Gordon A, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8
  18. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890–896
  19. Gonzalez-Billalabeitia E, Mendiola C, Mellado B, et al. A phase I/II clinical study of pegylated liposomal doxorubicin plus carboplatin in advanced ovarian cancer. Proc Am Soc Clin Oncol. 2003;22:[abstract 1919]
  20. Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol. 2007;18:263–268
  21. du Bois A, Pfisterer J, Burchardi N, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol. 2007;107:518–525
  22. Power P, Stuart G, Oza A, et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol. 2009;June 9 [Epub ahead of print]
  23. Rapoport BL, Vorobiof DA, Slabber C, et al. Phase II study of liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer. 2009;19:1137–1141
  24. Alberts DS, Liu PY, Wilczynski SP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol. 2008;108:90–94
  25. Linardou H, Bafaloukos D, Bamlas A, et al. A randomized phase II study of carboplatin plus liposomal doxorubicin (CLD) vs carboplatin plus paclitaxel (CP) in potentially platinum sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study. Eur J Cancer. 2007;5(Suppl.):312;[abstract 5003]
  26. Pujade-Lauraine E, Mahner S, Kaern J, et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol. 2009;27(18 Suppl.):799s;[abstract LBA5509]
  27. du Bois A, Burges A, Meier W, et al. Liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann Oncol. 2006;17:93–96
  28. Pignata S, Scambia G, Savarese A, et al. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer. 2006;6:202
  29. Pignata S, Scambia G, Savarese A, et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology. 2009;76:49–54
  30. Pignata S, Scambia G, Savarese A, et al. Carboplatin plus paclitaxel (CP) versus carboplatin and stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial. J Clin Oncol. 2009;27(18 Suppl.):798s;[abstract LBA5508]
  31. Le LH, Swenerton KD, Elit L, et al. Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer. 2005;15:799–806
  32. Verschraegen CF, Kavanagh JJ, Loyer E, et al. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001;92:2327–2333
  33. Pignata S, Scambia G, Pisano C, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96:1639–1643
  34. Geisler JP, Linnemeier GC, Thomas AJ, Manahan KJ. Extreme drug resistance is common after prior exposure to paclitaxel. Gynecol Oncol. 2007;106:538–540
  35. Horowitz NS, Hua J, Gibb RK, et al. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004;94:67–73
  36. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 1995;13:1584–1588
  37. See HT, Freedman RS, Kudelka AP, et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer. 2005;15:209–216

PII: S1040-8428(09)00176-0

doi: 10.1016/j.critrevonc.2009.08.004

Critical Reviews in Oncology / Hematology
Volume 73, Issue 1 , Pages 23-30 , January 2010

Article Tools

* Image Usage & Resolution